3,068
Views
3
CrossRef citations to date
0
Altmetric
Articles

Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States

, , , , , , ORCID Icon, & show all
Pages 2052-2062 | Received 07 Jan 2022, Accepted 22 Mar 2022, Published online: 14 Apr 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Rakesh Awasthi, Harald J. Maier, Jie Zhang & Stephen Lim. (2023) Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy. Human Vaccines & Immunotherapeutics 19:1.
Read now

Articles from other publishers (2)

Sérgio Chacim, Teresa Monjardino, José Luís Cunha, Pedro Medeiros, Patrícia Redondo, Maria José Bento & José Mário Mariz. (2022) Costs, effectiveness, and safety associated with Chimeric Antigen Receptor (CAR) T-cell therapy: Results from a comprehensive cancer center. PLOS ONE 17:12, pages e0278950.
Crossref
Mi Kwon, Gloria Iacoboni, Juan Luis Reguera, Lucía López Corral, Rafael Hernani Morales, Valentín Ortiz-Maldonado, Manuel Guerreiro, Ana Carolina Caballero, María Luisa Guerra Domínguez, Jose Maria Sanchez Pina, Alberto Mussetti, Juan Manuel Sancho, Mariana Bastos-Oreiro, Eva Catala, Javier Delgado, Hugo Luzardo Henriquez, Jaime Sanz, María Calbacho, Rebeca Bailén, Cecilia Carpio, Jose Maria Ribera, Anna Sureda, Javier Briones, Juan Carlos Hernandez-Boluda, Nuria Martínez Cebrián, Jose Luis Diez Martin, Alejandro Martín & Pere Barba. (2022) Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica 108:1, pages 110-121.
Crossref